tbuckley/cabot-search huggingface dataset:
Documentation of Pain in Comprehensive Cancer Centers in the United States: A Preliminary Analysis
Authors: Sharon M Weinstein, Dorothy Romanus, Eva M Lepisto, Cielito Reyes-Gibby, Charles Cleeland, Rex Greene, Cameron Muir, Joyce Niland
Journal: Journal of the National Comprehensive Cancer Network (2004)

The National Comprehensive Cancer Network (NCCN), an organization of 19 of the world's leading cancer centers, developed and communicated a cancer pain treatment guideline. NCCN seeks to implement guidelines through performance measurement using a NCCN Oncology Outcomes Database. This is a preliminary report from the NCCN Cancer Pain Management Database Project. The primary objective of this NCCN Cancer Pain Management Database Project study is to evaluate the frequency, methods, and extent of documentation of cancer pain assessment and managementat NCCN institutions. A pain data dictionary and related data collection forms were first developed. The records of 209 breast cancer patients with bone metastases were then studied. The frequency of pain mentions, type of pain assessment tool used, pain characteristics, type of clinician documenting pain, location in the medical record, and pain treatment characteristics were noted. The majority of clinical encounters included pain mentions, although considerable variability was found in pain documentation between providers and between inpatient and outpatient settings. Nurses more frequently recorded pain, usually as a numeric pain intensity score. Pain specialists were more likely to record a complete description of pain. A significant minority of patients experienced moderate to severe pain. In a small subgroup of patients with moderate to severe pain, pain treatment was not recorded. The undertreatment of cancer pain has been a focus of investigation and review for the past two decades. Quality improvement efforts to raise the standard of pain management have been underway. The results of this study highlight the need for standardization of pain documentation in comprehensive cancer centers as a prerequisite for the proper assessment of cancer pain and the improvement of clinical outcomes of pain management.
Acute Necrotizing Renal Papillitis Experimentally Produced in Rats Fed Mono-&lt;sc&gt;n&lt;/sc&gt;-Methylaniline
Authors: Julius White, Ph. D., Pablo Mori-Chavez, M. D.
Journal: JNCI Journal of the National Cancer Institute (1952)

Acute Necrotizing Renal Papillitis Experimentally Produced in Rats Fed Mono-n-Methylaniline Get access Julius White, Ph. D., Julius White, Ph. D. Laboratory of Biophysics Search for other works by this author on: Oxford Academic PubMed Google Scholar Pablo Mori-Chavez, M. D. Pablo Mori-Chavez, M. D. Research Fellow Laboratory of Pathology, National Cancer InstituteBethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 12, Issue 4, February 1952, Pages 777–787, https://doi.org/10.1093/jnci/12.4.777 Published: 01 February 1952 Article history Received: 01 October 1951 Published: 01 February 1952
Hepatic Lesions Caused by Protracted Ethionine Feeding&lt;xref ref-type="fn" rid="fn1"&gt;1&lt;/xref&gt;, &lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: Hans Popper, M.D., Clara Bruce
Journal: JNCI Journal of the National Cancer Institute (1955)

Journal Article Hepatic Lesions Caused by Protracted Ethionine Feeding, Get access Hans Popper, M.D., Hans Popper, M.D. Hektoen Institute for Medical Research of Cook County Hospital and the Departments of Pathology of Cook County Hospital and Northwestern University School of Medicine, Chicago, Ill. Search for other works by this author on: Oxford Academic PubMed Google Scholar Clara Bruce Clara Bruce Hektoen Institute for Medical Research of Cook County Hospital and the Departments of Pathology of Cook County Hospital and Northwestern University School of Medicine, Chicago, Ill. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue Supplement_5, April 1955, Pages 1597–1602, https://doi.org/10.1093/jnci/15.Supplement_5.1597 Published: 01 April 1955
Sequential Development of Ethylnitrosourea-Induced Neurinomas: Morphology, Biochemistry, and Transplantability2
Authors: James A. Swenberg, Nancy Clendenon, Robert Denlinger, Wanda A. Gordon
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Sequential Development of Ethylnitrosourea-Induced Neurinomas: Morphology, Biochemistry, and Transplantability Get access James A. Swenberg, James A. Swenberg Search for other works by this author on: Oxford Academic PubMed Google Scholar Nancy Clendenon, Nancy Clendenon Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert Denlinger, Robert Denlinger Search for other works by this author on: Oxford Academic PubMed Google Scholar Wanda A. Gordon Wanda A. Gordon Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 55, Issue 1, July 1975, Pages 147–152, https://doi.org/10.1093/jnci/55.1.147 Published: 01 July 1975 Article history Received: 18 December 1974 Accepted: 21 March 1975 Published: 01 July 1975
Board Certification in Child Psychiatry: Recent Developments
Authors: John F. Mcdermott, Christine Mcguire, Stuart M. Finch
Journal: American Journal of Psychiatry (1974)

The authors describe the evolvement of board certification procedures in child psychiatry and a nationwide three-year study undertaken by the Committee on Certification in Child Psychiatry of the American Board of Psychiatry and Neurology, Inc. The purpose of the study is to improve the validity and reliability of the Board examination, identify and incorporate new developments in the field in anticipation of future national requirements for periodic recertification, and generate data that will assist training directors to increase the efficiency and effectiveness of their programs.
Multimedia: Should Health Screening be Private?
Authors: John Cairns
Journal: BMJ (1999)

Jim Thornton


Institute of Economic Affairs, £5.60, pp 78 




ISBN 0 255 36451 2

———————

Rating: ★★

The NHS should stop screening for breast and cervical cancer. Indeed, the NHS should offer screening only in very limited circumstances, such as for adults only when the screening is of undisputed cost effectiveness and these adults could not otherwise afford it. Jim Thornton reaches these controversial conclusions largely because of his belief that consumers are the only people able to judge whether the benefits of screening outweigh the potential side effects. One consequence is that it is generally impossible to measure the ratio of costs to benefits of any screening programme.

This view of consumers raises several problems. There must be considerable doubt as to whether consumers have sufficient information to judge consistently what is in their best interests. In addition, although pregnant women would be deemed the best judges of their own welfare, they would not be considered the best judges of their babies’ welfare. Children should be protected from lazy and incompetent parents, but such people should not be protected from themselves. Thornton believes that publicly provided screening is coercive in nature and that, by implication, consumers will be screened when it may not be in their interests. But if consumers are the best judges will they not make the correct decision? There are also likely to be major practical difficulties distinguishing between someone unable to afford screening and someone choosing not to pay for screening because the benefits of screening are less than the benefits they would have to forego to pay for the screening.

It is not clear whether Thornton would extend his reasoning to other forms of health care or whether he regards screening as somehow special. Should the NHS as a whole provide care only for adults who cannot afford to pay for their own? One of the principles on which the NHS is based is that health care should be provided free at the time of use. This principle commands wide support, possibly because people feel better off living in a society where this holds true. If this is the case, the benefits of health care in general, and of screening in particular, are not purely private as Thornton claims.

Screening potentially affects most if not all of the population, and so a discussion of how it should be provided is of considerable potential interest. Readers of this essay will be encouraged to think a bit more about why they hold the views that they do, but I suspect that it will not lead to any changes in those views.
Case 14-1983
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, Andrew Huvos, Eugene J. Mark
Journal: New England Journal of Medicine (1983)

Presentation of CaseA 67-year-old woman was admitted to the hospital because of syncope on effort.There was a four-year history of Raynaud's phenomenon, for which bilateral dorsal sympathectomies were performed two years before admission. A preoperative electrocardiogram showed a normal rhythm at a rate of 65 per minute and was within normal limits aside from first-degree atrioventricular block (0.24 second). X-ray films of the chest revealed that the heart was not enlarged; several calcified granulomas were seen in the right-upper-lung field, and a single one was visible in the left-upper-lung field; calcifications were observed in the hilar regions, and . . .
Imaging of Scrub Typhus by PET/CT
Authors: Jing Lv, Shuai Liu, Yu Pan, Huijun Ju, Yifan Zhang
Journal: Clinical Nuclear Medicine (2015)

A 19-year-old man had an unexplained fever, dizziness, headache, fatigue, and pain in the scrotum. An FDG PET/CT imaging was acquired to assess fever of unknown origin. The images showed multiple foci of increased FDG activity in the enlarged lymph nodes in the body. In addition, mildly increased activity in the enlarged spleen and lung bases was also noted. The patient was eventually diagnosed with scrub typhus based on positive results of the Weil-Felix agglutination test, eschar in the scrotum, and effective therapy.
SAT0396 Anti-Annexin II: A Novel Marker in Antiphospholipid Syndrome
Authors: E. Soliman, A. Algerby, N. Mohannad
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Recently the role of anti-annexin II (AII) has been investigated in several autoimmune disorders. These antibodies were suspected to have a pathogenic potential, but their exact role in SLE and its association with thrombosis is still unclarified. <h3>Objectives</h3> To investigate the role of anti-A II antibodies in SLE patients with and without antiphospholipid syndrome (APS) in comparison with Anticardiolipins (Acl) antibodies, Anti-beta2 glycoprotien I (β2GPI) and Lupus Anticoagulant (LAC). <h3>Methods</h3> The study included 20 SLE patients with secondary APS, 20 SLE patients without any history of thrombosis and 10 age and sex matched healthy controls. Acl, LAC, β2GPI and Anti-AII antibodies were tested in all patients and controls. <h3>Results</h3> There was a significantly higher mean levels of anti-AII in SLE patients with secondary APS than SLE without APS (1.575±0.769 and 0.765±0.664 respectively, P=0.032) and higher than controls (0.300±0.047, P=0.0031). Anti-AII antibodies were significantly more prevalent than other antibodies (table 1) in patients with SLE and APS than in SLE without thrombotic events (80% versus 40% respectively, P=0.0098) and controls (0%, P=0.0001), especially those with recurrent venous thrombosis and recurrent abortions. Compared to conventional markers for APS, anti-AII had the highest sensitivity, specificity and positive predictive value (PPV) (92%, 77.8%, 88.0% respectively) for APS. (table 2) <h3>Conclusions</h3> Anti-AII is significantly increased in SLE with thrombosis compared to the conventional antibodies. Moreover, they showed the highest sensitivity, specificity and PPV for APS. This suggests a potential role of anti-AII as a novel marker for identifying APS, which could provide a target for new therapies. Further studies to test the diagnostic value of anti-AII in sero- negative APS are needed. <h3>Disclosure of Interest</h3> None declared
OP0099-HPR Fatigue in Adult Idiopathic Inflammatory Myopathies
Authors: H. Alexanderson, Å. Björklund, C. Ottosson, M. Dastmalchi, I.E. Lundberg
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Patients with adult polymyositis (PM), dermatomyositis (DM) and inclusion body myopathies (IBM) have reduced quality of life. Fatigue is an often disabling symptom in other inflammatory rheumatic conditions such as rheumatoid arthritis, however the contribution of fatigue on quality of life in patients with myositis is largely unknown. <h3>Objectives</h3> To evaluate fatigue severity in PM, DM and IBM and to compare with population-based reference values, to evaluate a possible difference in fatigue between the myositis entities and gender, to evaluate correlations between fatigue and muscle function, disease activity and other aspects of quality of life and to study how fatigue develops over time. <h3>Methods</h3> All patients registered in the Swedish Myositis register at the Karolinska University Hospital, n=80 (PM, n=46, DM, n=27, IBM, n=7) (55 women/ 25 men) who had completed the SF-36 survey during 2013 during a yearly check-up were included in this study. They had a median age of 62 (q1-q3 54-70.5) years, a median diagnosis duration of 8 (4.5-15.5) years and a median disease activity of 6 (0-15) mm (VAS physician9s global assessment). Data on fatigue (SF-36 Vitality, 0-100 where 100 equals no fatigue), and muscle endurance (Functional Index 2, FI-2) were also collected. All patients who had completed the SF-36 survey at both 2009 and 2013 (n=41) were included to study how fatigue changes over time. <h3>Results</h3> Patients had worse fatigue on the SF-36 Vitality, (median 50 (30-70)/mean 50±26) compared to population-based reference values (mean 67±20) (p&lt;0.001). There was no difference in fatigue between patients with PM, DM and IBM (medians 48 (30-70), 50 (35-80) and 45 (35-50), respectively or between men, 50 (30-80) and women 50 (35-70). Correlations between the SF-36 Vitality and the other SF-36 domains varied between r<sub>s</sub>=0.54-0.75 with highest correlations to Mental health (r<sub>s</sub>=0.75) and Social function (<sub>rs</sub>=0.66). Correlations between the SF-36 Vitality and the FI-2, the HAQ and the physician VAS varied between r<sub>s</sub>=0.46-0.48 with lower correlations to prednisolone dose, diagnosis duration and age (r<sub>s</sub>=0.35, 0.01, &lt;0.01, respectively). There was no significant change in fatigue over five years, median 50 (35-72.5) compared to 45 (20-60). <h3>Conclusions</h3> Patients with PM, DM and IBM have significantly worse fatigue than the reference population, with no difference between sub-diagnosis and gender. Fatigue correlated best to mental health and social function. Fatigue scores were unchanged over five years. Fatigue seems to have an impact on quality of life and function in adult myositis and needs to be addressed in clinical care and should be a subject for future research. <h3>Disclosure of Interest</h3> None declared
Response to 13-cis-retinoic acid plus interferon alfa-2a in two patients with therapy-refractory advanced renal cell carcinoma.
Authors: J Buer, M Probst, A Ganser, J Atzpodien
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.10.2679 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7595723 Response to 13-cis-retinoic acid plus interferon alfa-2a in two patients with therapy-refractory advanced renal cell carcinoma. J BuerxJ BuerSearch for articles by this author , M ProbstxM ProbstSearch for articles by this author , A GanserxA GanserSearch for articles by this author , J AtzpodienxJ AtzpodienSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.10.2679 PDF "Response to 13-cis-retinoic acid plus interferon alfa-2a in two patients with therapy-refractory advanced renal cell carcinoma.." Journal of Clinical Oncology, 13(10), pp. 2679–2680© 1995 by American Society of Clinical Oncology
Effects of Depot Injections of Retinyl Palmitate on 7,12-Dimethylbenz[a]anthracene-induced Preneoplastic Changes in Rat Skin2
Authors: Irene V. Brown, Bernard P. Lane, John Pearson
Journal: JNCI Journal of the National Cancer Institute (1977)

The preneoplastic skin changes usually induced by topical application of 7,12-dimethylbenz[a]anthracene (DMBA) to adult rat skin did not appear when animals were treated locally with depot im injections of high doses of retinyl palmitate (RP) prior to exposure to the carcinogen. The epidermal histology after RP-DMBA treatment was similar to that seen in areas exposed to RP alone. Keratinization was inhibited but there was no cellular atypia, evidence of cell injury, or mucous metaplasia. Other features were hyperplasia with acanthosis and thickened stratum granulosum, parakeratosis, intercellular edema, and loss of hair overlying the injection site. Ultrastructurally, the epidermal cells contained conspicuously fewer tonofibrils and increased dense chromatin, when compared to control cells. Skin changes observed following treatment of littermates with DMBA alone included the appearance of giant tumor cells, dyskeratotic cells, nuclear hyperchromatism, increased nucleocytoplasmic ratio, and pleomorphic nuclei and nucleoli. Loss of desmosomes, increased tonofibrils, and defects in the basement membrane with epithelial projections into the dermis were also seen. These preneoplastic changes did not regress when application with DMBA was discontinued after 6 weeks; exposure to the carcinogen for longer than 6 weeks resulted in an exacerbation of the abnormal state. RP had profound effects on rat epidermis that interfered with the effects of a potent skin carcinogen. The mechanisms underlying the phenomenon have not been defined. The use of depot injections of the vitamin which avoids both systemic toxicity and the local irritation seen with topical exposure could serve as a model in which the anticarcinogenesis properties of retinoids could be explored.
Use of mental health services for the treatment of panic disorder
Authors: J H Boyd
Journal: American Journal of Psychiatry (1986)

The author reports the results of five studies of panic disorder undertaken as part of the Epidemiologic Catchment Area Program of the National Institute of Mental Health (NIMH). This program involves community samples in New Haven, Conn. (N = 5,034), Baltimore (N = 3,481), St. Louis (N = 3,004), Durham, N.C. (N = 3,921), and Los Angeles (N = 3,132). Diagnoses were based on the NIMH Diagnostic Interview Schedule and DSM-III. Panic disorder led the list of disorders for which subjects in the five studies received ambulatory mental health services. Treatment rates for panic disorder were as high as or higher than those for somatization disorder, schizophrenia, and major affective disorders. Furthermore, panic attacks may have been the reason that many subjects with other disorders sought treatment.
Elevated serum ras level predicts decreased survival in patients with hematologic malignancies
Authors: E. M. Nelli, K. Leitzel, S. M. Ali, H. A. Al-Mondhiry, L. Demers, H. A. Harvey, W. P. Carney, P. J. Hamer, A. Lipton
Journal: Journal of Clinical Oncology (2006)

6562 Background: Ras is a GDP/GTP binding G protein that acts as a molecular switch converting signals from the cell membrane to the nucleus to regulate cell proliferation, differentiation, and protein synthesis. Activation of ras oncogenes has been identified in a variety of cancers, including 30% of acute myelogenous leukemia patients. The purpose of our study was to evaluate serum ras levels and correlate with survival in hematologic cancer patients. Methods: A novel ras p21 ELISA (Oncogene Science/Bayer Diagnostics, Cambridge, MA) employing two monoclonal antibodies reactive with H, K, and N ras was utilized to quantify total ras levels in serum obtained from patients with various hematologic malignancies including acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and chronic lymphocytic leukemia (CLL). Results: The total leukemia patient group consisted of 52 patients. At the 75th percentile serum ras cutpoint (524 pg/ml) 11/52 patients were defined as elevated for serum ras. From this patient group, 38 patients had clinical followup available and were included in the Kaplan-Meier analysis of overall survival. Patients with elevated serum ras (&gt;524 pg/ml) had significantly shorter overall survival compared to those without (median OS 205 vs. 677 days) (p= 0.04). In a multivariate analysis including serum ras level and type of leukemia, serum ras level remained a significant independent variable for shorter overall survival (p=0.004). Within leukemia subtypes 2/18 AML, 4/9 CML, 3/7 ALL, and 0/4 CLL patients had elevated serum ras levels. Conclusions: Leukemia patients with elevated serum ras levels had a significantly shorter overall survival. Serum ras should be evaluated as a potential biomarker in larger leukemia trials, especially for response to treatment with inhibitors of the ras signaling pathway. [Table: see text]
Adverse Effects of Proton Pump Inhibitors in Chronic Kidney Disease
Authors: Eivind Ness-Jensen, Reidar Fossmark
Journal: JAMA Internal Medicine (2016)

To the Editor We read with interest the article by Lazarus et al in a recent issue of JAMA Internal Medicine.1 We believe this is a well-done study with a good design and sound methods, but we have some remarks and suggestions that may be of importance.
AB0609 Saliva Variations May Make Gastro-Esophageal Reflux Disease in Sjögren Syndrome
Authors: S.Y. Lee, W.T. Chung, S.W. Lee
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The protective role of saliva in the case of esophageal exposition to gastric acid has long been studied but some contradictions still remain. <h3>Objectives</h3> The main end-point of this study was to evaluate if a qualitative and quantitative alteration in salivary secretion exists in sjögren syndrome patients affected by gastro-esophageal reflux disease (GERD). <h3>Methods</h3> 20 sjögren syndrome patients with endoscopically diagnosed GERD (LA classification A-D) and 10 sjögren syndrome patients without GERD have been evaluated; salivary tests (basal flow rate, stimulated flow rate, pH, [Na+] and [K+]) were performed, socio-demographical variables and oral GERD-related symptoms were taken into account. <h3>Results</h3> Sjögren syndrome patients with GERD and sjögren syndrome patients without GERD were found to have a similar basal flow rate but different stimulated salivary function [sjögren syndrome with GERD group mean value 0.989 ml/min (±0.48718) vs. sjögren syndrome without GERD group 1.2197 ml/min (±0.6108), pH [sjögren syndrome group mean value 8.935 (±0.471) vs. sjögren syndrome without GERD group 7.879 (±0.526)] and a higher K+ concentration. In sjögren syndrome with GERD patients we also registered a significant association with severe xerostomia [18/20 vs. 3/10] and severe an oral burning sensation [17/20 vs. 2/10]. <h3>Conclusions</h3> Our findings assess that variation of saliva is altered in sjögren syndrome with GERD patients and highlight the need for further investigations in order to define the role of saliva in the etiology of GERD in sjögren syndrome. <h3>References</h3> Early events in Sjögren9s Syndrome pathogenesis: The importance of innate immunity in disease initiation. Cytokine 67 (2014) 92–101. <h3>Disclosure of Interest</h3> None declared